Find 41 companies with promising cash flow potential yet trading below their fair value.
To own LifeStance Health, you need to believe in the long-term demand for accessible behavioral health care and the company’s ability to scale profitably while integrating acquisitions and new markets. The story has recently been about execution: LifeStance has turned profitable, raised its 2026 revenue guidance, and is actively buying back shares while pursuing tuck-in deals to deepen its footprint. The late-June removal from multiple Russell indices complicates the near-term picture, as some passive and benchmark-aware investors may reduce exposure even after strong recent share price gains. That could shift the short-term catalyst mix away from index-driven flows and back toward fundamentals like sustaining revenue growth, margin progress and disciplined M&A following the large follow-on offerings. At the same time, it slightly sharpens existing risks around valuation, liquidity and a relatively new management team.
However, the combination of a richer valuation and index removal is something investors should watch closely. LifeStance Health Group's shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.Four fair value estimates from the Simply Wall St Community span roughly US$0.39 to US$10.55, underscoring how far apart views can be. Set against recent index removal and an already full sales multiple, these differing opinions highlight why many readers may want to weigh several perspectives before deciding how LifeStance’s execution and risk profile fit their own expectations.
Explore 4 other fair value estimates on LifeStance Health Group - why the stock might be worth less than half the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com